Our achievements

Since 2013, Bioxodes has been developing its main Ir-CPI preclinical program for acute antithrombotic indications and is now entering preclinical toxicology and safety pharmacology studies. In parallel, Bioxodes has been developing other drug candidates for chronic antithrombotic indications.

Enregistrer